Announced Date: 2022-05-16 (May 16, 2022)
Asset Name: SKB-315 (MK-1200)
Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd, China)
Licensee (Buyer): MSD (Merck & Co., Inc. USA)
.
Asset Modality: Antibody drug conjugate (ADC)
Asset Target: Claudin18.2
Current Stage:
Scope of Authority:
Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational ADC.
Kelun-Biotech and MSD will also collaborate on the early clinical development of the investigational ADC.
.
Deal Detail:
Upfront payment of $47 million,
Milestone payments up to $1.363 billion,
Plus tiered royalties on net sales.
.
Link:
Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD
Note:
Kelun-Biotech (Chinese Name: 科伦博泰）
